Background and Objective: Asthma is a chronic airway disease with increasing cases in children, differing from adult-onset asthma in triggers and outcomes. This study focuses on the rs7216389 variant of the GSDMB gene, exploring its role in airway inflammation and its clinical and genetic links to pediatric asthma, with implications for improved diagnosis and targeted treatment.

Methodology: A case-control study spanning 18 months was carried out at CMH Lahore and Children’s Hospital, comprising 200 participants (100 with asthma and 100 healthy controls) aged 3–18 years. Genetic evaluation was conducted on blood specimens, and data analysis was executed using SPSS (v25.0). A p-value of less than 0.5 was considered significant. Ethical clearance was secured, and informed consent was acquired.

Results: The study identifies the GSDMB variant rs7216389 as a potential genetic marker for asthma, emphasizing its association with the severity of the condition in children. It highlights the challenges of translating genetic findings into clinical practice while emphasizing the therapeutic potential of targeting these genetic markers. The study also sheds light on healthcare costs and the distinctive clinical features of pediatric asthma, further contextualizing its impact.

Conclusion: This article offers a comprehensive examination of asthma pathogenesis, highlighting rs7216389 in the GSDMB gene as a key genetic contributor. Future research must study how genetics and environment, together with immune processes, influence childhood asthma because researchers aim to create specific treatment methods to reduce its impact.

TBA